These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 30107762)

  • 1. Comparative effectiveness of avelumab versus chemotherapy in Merkel cell carcinoma: innovative use of patient insights.
    Bharmal M; Marrel A; Hennessy M; Fofana F; Lambert J; Arnould B
    J Comp Eff Res; 2018 Sep; 7(9):881-890. PubMed ID: 30107762
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Patient Experiences with Avelumab in Treatment-Naïve Metastatic Merkel Cell Carcinoma: Longitudinal Qualitative Interview Findings from JAVELIN Merkel 200, a Registrational Clinical Trial.
    Lambert J; Marrel A; D'Angelo SP; Burgess MA; Chmielowski B; Fazio N; Gambichler T; Grob JJ; Lebbé C; Robert C; Russell J; Güzel G; Bharmal M
    Patient; 2020 Aug; 13(4):457-467. PubMed ID: 32472503
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Updated efficacy of avelumab in patients with previously treated metastatic Merkel cell carcinoma after ≥1 year of follow-up: JAVELIN Merkel 200, a phase 2 clinical trial.
    Kaufman HL; Russell JS; Hamid O; Bhatia S; Terheyden P; D'Angelo SP; Shih KC; Lebbé C; Milella M; Brownell I; Lewis KD; Lorch JH; von Heydebreck A; Hennessy M; Nghiem P
    J Immunother Cancer; 2018 Jan; 6(1):7. PubMed ID: 29347993
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and Safety of First-line Avelumab Treatment in Patients With Stage IV Metastatic Merkel Cell Carcinoma: A Preplanned Interim Analysis of a Clinical Trial.
    D'Angelo SP; Russell J; Lebbé C; Chmielowski B; Gambichler T; Grob JJ; Kiecker F; Rabinowits G; Terheyden P; Zwiener I; Bajars M; Hennessy M; Kaufman HL
    JAMA Oncol; 2018 Sep; 4(9):e180077. PubMed ID: 29566106
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real-World Clinical Outcomes in Patients with Locally Advanced or Metastatic Merkel Cell Carcinoma Treated in U.S. Oncology Clinical Practices: Results from SPEAR-Merkel.
    Bhanegaonkar A; Liu FX; Boyd M; Fulcher N; Kim R; Krulewicz S; Smith J; Cowey CL
    Oncologist; 2021 Sep; 26(9):e1633-e1643. PubMed ID: 34101298
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Avelumab Immunotherapy: Management of Adverse Events Associated With New Treatment for Merkel Cell Carcinoma.
    Ugolini H; Bryan J; Hennessy M; Kaufman HL; D'Angelo S
    Clin J Oncol Nurs; 2019 Feb; 23(1):E1-E9. PubMed ID: 30682006
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A cost-utility analysis of avelumab for metastatic Merkel cell carcinoma in Taiwan.
    Chang WC; Lin AY; Hsu JC; Wu CE; Goh C; Chou P; Kuo K; Chang A; Palencia R
    Cancer Rep (Hoboken); 2021 Dec; 4(6):e1399. PubMed ID: 33934577
    [TBL] [Abstract][Full Text] [Related]  

  • 8. First-line avelumab treatment in patients with metastatic Merkel cell carcinoma: 4-year follow-up from part B of the JAVELIN Merkel 200 study.
    D'Angelo SP; Lebbé C; Mortier L; Brohl AS; Fazio N; Grob JJ; Prinzi N; Hanna GJ; Hassel JC; Kiecker F; von Heydebreck A; Güzel G; Nghiem P
    ESMO Open; 2024 May; 9(5):103461. PubMed ID: 38744102
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Avelumab in patients with previously treated metastatic Merkel cell carcinoma (JAVELIN Merkel 200): updated overall survival data after >5 years of follow-up.
    D'Angelo SP; Bhatia S; Brohl AS; Hamid O; Mehnert JM; Terheyden P; Shih KC; Brownell I; Lebbé C; Lewis KD; Linette GP; Milella M; Xiong H; Guezel G; Nghiem PT
    ESMO Open; 2021 Dec; 6(6):100290. PubMed ID: 34715570
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Avelumab treatment in Italian patients with metastatic Merkel cell carcinoma: experience from an expanded access program.
    Grignani G; Chiarion Sileni V; Pinto C; Depenni R; Fazio N; Galli L; Giuffrida D; Carnaghi C; Ciliberto D; Corsi DC; Queirolo P; Benincasa E; Venturini F; Fazzi G; Costa N; Ascierto PA
    J Transl Med; 2021 Feb; 19(1):70. PubMed ID: 33588870
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Avelumab for the treatment of metastatic Merkel cell carcinoma.
    Cordes LM; Gulley JL
    Drugs Today (Barc); 2017 Jul; 53(7):377-383. PubMed ID: 28837181
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real-world clinical outcomes with first-line avelumab in locally advanced/metastatic Merkel cell carcinoma in the USA: SPEAR-Merkel.
    Cowey CL; Liu FX; Kim R; Boyd M; Fulcher N; Krulewicz S; Kasturi V; Bhanegaonkar A
    Future Oncol; 2021 Jun; 17(18):2339-2350. PubMed ID: 33709776
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial.
    Kaufman HL; Russell J; Hamid O; Bhatia S; Terheyden P; D'Angelo SP; Shih KC; Lebbé C; Linette GP; Milella M; Brownell I; Lewis KD; Lorch JH; Chin K; Mahnke L; von Heydebreck A; Cuillerot JM; Nghiem P
    Lancet Oncol; 2016 Oct; 17(10):1374-1385. PubMed ID: 27592805
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Avelumab: A Review in Metastatic Merkel Cell Carcinoma.
    Shirley M
    Target Oncol; 2018 Jun; 13(3):409-416. PubMed ID: 29799096
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Survival Analysis in Patients with Metastatic Merkel Cell Carcinoma Treated with Avelumab.
    Lanitis T; Proskorovsky I; Ambavane A; Hunger M; Zheng Y; Bharmal M; Phatak H
    Adv Ther; 2019 Sep; 36(9):2327-2341. PubMed ID: 31350728
    [TBL] [Abstract][Full Text] [Related]  

  • 16. How to address the challenges of evaluating treatment benefits-risks in rare diseases? A convergent mixed methods approach applied within a Merkel cell carcinoma phase 2 clinical trial.
    Bharmal M; Guillemin I; Marrel A; Arnould B; Lambert J; Hennessy M; Fofana F
    Orphanet J Rare Dis; 2018 Jun; 13(1):95. PubMed ID: 29914528
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Avelumab expanded access program in metastatic Merkel cell carcinoma: Efficacy and safety findings from patients in Europe and the Middle East.
    Ascierto PA; Orlova K; Grignani G; Dudzisz-Śledź M; Fenig E; Chiarion Sileni V; Fazio N; Samimi M; Mortier L; Gebhardt C; Kramkimel N; Steven N; Bechter O; Arance A; Benincasa E; Kostkova L; Costa N; Lorigan P
    Int J Cancer; 2021 Dec; 149(11):1926-1934. PubMed ID: 34310716
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PD-L1 inhibition with avelumab for metastatic Merkel cell carcinoma.
    Gaiser MR; Bongiorno M; Brownell I
    Expert Rev Clin Pharmacol; 2018 Apr; 11(4):345-359. PubMed ID: 29478343
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Merkel cell carcinoma in Latin America: a contribution from an expanded access program for avelumab to address issues from experts' recommendations.
    Munhoz RR; Cayol F; Corrales L; Gerson R; Tilli M; Barreto EO; Sánchez Castillo JO; Schmerling RA; Cinat G
    Cancer Immunol Immunother; 2021 Apr; 70(4):1031-1036. PubMed ID: 33104838
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Avelumab: A Novel Anti-PD-L1 Agent in the Treatment of Merkel Cell Carcinoma and Urothelial Cell Carcinoma.
    Teets A; Pham L; Tran EL; Hochmuth L; Deshmukh R
    Crit Rev Immunol; 2018; 38(3):159-206. PubMed ID: 30004857
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.